Business Context and Reporting Period
This Form 8-K filing by EyePoint Pharmaceuticals, Inc. (EYPT) is dated June 12, 2020. The report addresses a notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock listing compliance rather than financial performance metrics.
Material Changes
The material event reported is the failure of the Company's common stock to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days prior to June 12, 2020, pursuant to Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Timeline: Due to temporary relief granted by Nasdaq through June 30, 2020, the Company's compliance period to regain the $1.00 minimum bid price begins July 1, 2020, and expires on December 28, 2020.
- Remediation Options: The Company intends to monitor the bid price and may consider effecting a reverse stock split if necessary to regain compliance.
- Delisting Risk: If compliance is not demonstrated by December 28, 2020, the Company may be eligible for a second compliance period by transferring to the Nasdaq Capital Market, subject to meeting other listing standards. Failure to qualify for this extension could result in delisting.
- Appeal Process: If delisting is determined, the Company may appeal to a Nasdaq Hearings Panel, though there is no assurance of success.
Investor Verification Checklist
- Verify the current trading price of EYPT common stock relative to the $1.00 minimum bid price requirement.
- Monitor Company announcements regarding the potential implementation of a reverse stock split before the December 28, 2020 deadline.
- Review the Company's ability to meet other Nasdaq Capital Market listing standards (e.g., market value of publicly held shares) if a transfer is required.
- Check for any subsequent filings regarding the outcome of the compliance period or potential delisting appeals.